Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Barinthus Biotherapeutics plc - American Depositary Shares
(NQ:
BRNS
)
1.280
UNCHANGED
Streaming Delayed Price
Updated: 3:56 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Barinthus Biotherapeutics plc - American Depositary Shares
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
May 22, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
March 20, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
New partnership aims to advance vaccine against MERS coronavirus
December 21, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.